Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-02. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
=== Parallel MRI === It takes time to gather MRI data using sequential applications of magnetic field gradients. Even for the most streamlined of MRI sequences, there are physical and physiologic limits to the rate of gradient switching. Parallel MRI circumvents these limits by gathering some portion of the data simultaneously, rather than in a traditional sequential fashion. This is accomplished using arrays of radiofrequency (RF) detector coils, each with a different 'view' of the body. A reduced set of gradient steps is applied, and the remaining spatial information is filled in by combining signals from various coils, based on their known spatial sensitivity patterns. The resulting acceleration is limited by the number of coils and by the signal to noise ratio (which decreases with increasing acceleration), but two- to four-fold accelerations may commonly be achieved with suitable coil array configurations, and substantially higher accelerations have been demonstrated with specialized coil arrays. Parallel MRI may be used with most MRI sequences. After a number of early suggestions for using arrays of detectors to accelerate imaging went largely unremarked in the MRI field, parallel imaging saw widespread development and application following the introduction of the simultaneous acquisition of spatial harmonics (SMASH) technique in 1996–7. The sensitivity encoding (SENSE) and generalized autocalibrating partially parallel acquisitions (GRAPPA) techniques are the parallel imaging methods in most common use today.
...it is better to fight to the last man and the last cartridge and die with some honour. Because, what is being presented to us here is a degree of humiliation... Van der Byl eventually retired to his country estate outside Cape Town, but there were elements in Rhodesia, mainly embittered former security force personnel, who forcibly opposed majority rule up to and well beyond the establishment of majority rule. New white immigrants continued to arrive in Rhodesia right up to the eve of majority rule.
==== Sleep ==== Sleep disturbances are seen as a possible risk factor for inflammation in Alzheimer's disease. Sleep disruption was previously only seen as a consequence of Alzheimer's disease, but as of 2020, accumulating evidence suggests that this relationship may be bidirectional.
== Signs and symptoms == Sydenham's chorea is characterized by the abrupt onset (sometimes within a few hours) of neurological symptoms, classically chorea, which are non-rhythmic, writhing or explosive involuntary movements. Usually all four limbs are affected, but there are cases reported where just one side of the body is affected (hemichorea). Typical chorea includes repeated wrist hyperextension, grimacing, and lip pouting. The fingers can move as if playing the piano. There may be tongue fasciculations ("bag of worms") and motor impersistence, for example, the "milkmaid sign" (grip strength fluctuates, as if hand milking a cow), or inability to sustain tongue protrusion (called jack-in-the-box tongue or serpentine tongue, as the tongue slides in and out of the mouth), or eye closure. There is usually a loss of fine motor control, which is particularly obvious in handwriting if the child is of school age. Speech is often affected (dysarthria), as is walking; legs will suddenly give way or flick out to one side, giving an irregular gait and the appearance of skipping or dancing. Underlying the abnormal movements is often low tone (hypotonia) which may not become obvious until treatment is started to suppress the chorea. The severity of the condition can vary from just some instability on walking and difficulty with handwriting, to the extreme of being wholly unable to walk, talk, or eat (chorea paralytica). Movements cease during sleep.
Almost all saffron grows in a belt stretching from Spain in the west to India in the east. Iran is responsible for around 90% of global production, and in 2024 was the largest producer, followed by Afghanistan. Saffron is cultivated in 26 of Afghanistan's 34 provinces, with most production concentrated in Herat. Greece is the third largest producer, followed by Spain, which was once the largest producer in the 19th century. Other producers include the United Arab Emirates, the Indian subcontinent (particularly Kashmir), and Morocco.
Sources: en.wikipedia.org
Having lost 20 million people in the war, suffered German invasion twice in 30 years, and suffered tens of millions of casualties from onslaughts from the West three times in the preceding 150 years, the Soviet Union was determined to destroy Germany's capacity for another war. This was in alignment with the Allied policy which had foreseen returning Germany to a pastoral state without heavy industry (the Morgenthau Plan). On September 6, 1946, US Secretary of State James F. Byrnes made a speech in Germany, repudiating the Morgenthau Plan and warning the Soviets that the US intended to maintain a military presence in Europe indefinitely. (see Restatement of Policy on Germany) As Byrnes admitted one month later, "The nub of our program was to win the German people [...] it was a battle between us and Russia over minds ...". Because of the increasing costs of food imports to avoid mass-starvation in Germany, and with the danger of losing the entire nation to communism, the US government abandoned the Morgenthau plan in September 1946 with Secretary of State James F. Byrnes's speech Restatement of Policy on Germany. In January 1947, Truman appointed General George Marshall as Secretary of State, scrapped Joint Chiefs of Staff (JCS) directive 1067, which embodied the Morgenthau Plan and supplanted it with JCS 1779, which decreed that an orderly and prosperous Europe requires the economic contributions of a stable and productive Germany".
CCK also causes the increased production of hepatic bile, and stimulates the contraction of the gall bladder and the relaxation of the sphincter of Oddi (Glisson's sphincter), resulting in the delivery of bile into the duodenal part of the small intestine. Bile salts form amphipathic lipids, micelles that emulsify fats, aiding in their digestion and absorption.
Flutamide acts as a selective, competitive, silent antagonist of the androgen receptor (AR). Its active form, hydroxyflutamide, has between 10- and 25-fold higher affinity for the AR than does flutamide, and hence is a much more potent AR antagonist in comparison. However, at high concentrations, unlike flutamide, hydroxyflutamide is able to weakly activate the AR. Flutamide has far lower affinity for the AR than do steroidal antiandrogens like spironolactone and cyproterone acetate, and it is a relatively weak antiandrogen in terms of potency by weight, but the large dosages at which flutamide is used appear to compensate for this. In accordance with its selectivity for the AR, flutamide does not interact with the progesterone, estrogen, glucocorticoid, or mineralocorticoid receptor, and possesses no intrinsic progestogenic, estrogenic, glucocorticoid, or antigonadotropic activity. However, it can have some indirect estrogenic effects via increased levels of estradiol secondary to AR blockade, and this involved in the gynecomastia it can produce. Because flutamide does not have any estrogenic, progestogenic, or antigonadotropic activity, the medication does not cause menstrual irregularities in women. This is in contrast to steroidal antiandrogens like spironolactone and cyproterone acetate. Similarly to nilutamide, bicalutamide, and enzalutamide, flutamide crosses the blood–brain barrier and exerts central antiandrogen actions.
==== Surgical ==== There are many surgical options available for the treatment of uterine prolapse, which may be performed through a vaginal procedure or through the abdomen. Generally, vaginal procedures are considered to be less invasive, offer a quicker recovery, and have a shorter operative time compared to abdominal procedures, but abdominal procedures offer longer-term results and potentially reduce risk of postoperative vaginal pain with intercourse. Laparoscopic and robotic approaches to abdominal procedures in prolapse surgery have become more common as they require smaller incision sites, result in less blood loss, and have shorter hospital stays. If a hysterectomy is performed, a vaginal vault suspension (known as colpopexy), in which the upper portion of the vagina is surgically connected to another structure in the pelvis, is commonly performed to prevent vaginal vault prolapse in the future. Forms of colpopexy include sacrocolpopexy, in which the vaginal vault is attached to the sacrum using a surgical mesh; sacrospinous ligament fixation, in which the upper vagina is attached to the sacrospinous ligaments using sutures; and uterosacral ligament vaginal vault suspension, in which the upper vagina is attached to the uterosacral ligaments using sutures. Colpopexy can be performed with or without a hysterectomy. If performed without a hysterectomy, the procedure is known as a hysteropexy. Hysteropexy procedures include sacrohysteropexy and sacrospinous hysteropexy.
=== Automation === The technology has been automated, leading to a dramatic increase in the efficiency of amplification. Now, a single cycle results in a 2500-fold increase in sensitivity of detection over western blotting, whereas 2 and 7 consecutive cycles result in 6 million and 3 billion-fold increases in sensitivity of detection over western blotting, a technique widely used in BSE surveillance in several countries.
Sources: en.wikipedia.org
Per Baseball Reference, Bagwell's 79.6 Wins Above Replacement (WAR) ranks sixth-most all-time among first basemen, trailing only Lou Gehrig, Albert Pujols, Jimmie Foxx, Cap Anson, and Roger Connor. He spent the first nine seasons of his career (1991–99) playing home games at the Astrodome, notorious for its reputation as the toughest park in which to hit when baseball was still played there. However, during those nine years, his production at home was nearly identical to his production on the road. In that same period of time, his 160 OPS+ was fourth behind Bonds, McGwire, and Frank Thomas; his 56.7 WAR was third behind Bonds and Ken Griffey Jr. From 1994 to 2000, a span including his age-26 through age-32 seasons, he averaged 41 home runs and 41 doubles per 162 games while batting .309, .433 OBP, and .593 SLG for a 167 OPS+. Over his career, Bagwell batted at least .300 six times, amassed a 1.000 OPS five times, collected at least 30 home runs eight times, 100 RBI eight times, 100 runs scored nine times, and 100 walks seven times. He is the only player in history to achieve six consecutive seasons (1996–2001) with each of 30 home runs, 100 RBI, 100 runs scored, and 100 walks. Bagwell had seven seasons with 30 home runs and 100 walks; the only players with more are Gehrig, Ruth, Williams, Jim Thome, and Thomas. Bagwell is one of 12 players in MLB history to hit at 400 home runs and attain a career on-base percentage of at least .400. The only National League first baseman to reach the 30–30 club, he is the only first baseman in history to do it twice.
The Cantley lab also was one of a few labs that nearly simultaneously identified LKB1 as a regulator of AMPK that also serves to regulate TORC1. For the discovery of PI-3-Kinase and its role in cancer metabolism, Cantley was one of eleven recipients of the inaugural Breakthrough Prize in Life Sciences, "the world's richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life." The fundamental and far-reaching nature of the discovery of PI-3-kinase, together with Cantley's role in mapping the upstream regulation of PI-3-kinase and the downstream signaling pathways, have led to speculation that Cantley is a likely candidate for the Nobel prize in Medicine or Physiology. The growing evidence for a primary role for PI-3-kinase in cancer and its critical role in insulin signaling have served to strengthen the significance of this fundamentally important discovery. The first drug targeting the PI-3-kinase pathway as a treatment for cancer – Idelalisib (PI3K Delta inhibitor) – was approved by the FDA as a treatment for leukemia and two types of lymphoma in July 2014. Other drugs are currently in clinical development.
Auxins are compounds that positively influence cell enlargement, bud formation, and root initiation. They also promote the production of other hormones and, in conjunction with cytokinins, control the growth of stems, roots, and fruits, and convert stems into flowers. Auxins were the first class of growth regulators discovered. A Dutch Biologist Frits Warmolt Went first described auxins. They affect cell elongation by altering cell wall plasticity. They stimulate cambium, a subtype of meristem cells, to divide, and in stems cause secondary xylem to differentiate. Auxins act to inhibit the growth of buds lower down the stems in a phenomenon known as apical dominance, and also to promote lateral and adventitious root development and growth. Leaf abscission is initiated by the growing point of a plant ceasing to produce auxins. Auxins in seeds regulate specific protein synthesis, as they develop within the flower after pollination, causing the flower to develop a fruit to contain the developing seeds. In large concentrations, auxins are often toxic to plants; they are most toxic to dicots and less so to monocots. Because of this property, synthetic auxin herbicides including 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) have been developed and used for weed control by defoliation. Auxins, especially 1-naphthaleneacetic acid (NAA) and indole-3-butyric acid (IBA), are also commonly applied to stimulate root growth when taking cuttings of plants. The most common auxin found in plants is indole-3-acetic acid (IAA).
== History == From 1946 to 1948, the eleven states formed a single British crown colony known as the Malayan Union. Due to opposition from Malay nationalists, the Union was disbanded and replaced by the Federation of Malaya, which restored the symbolic positions of the rulers of the Malay states and introduced greater restrictions on the attainment of citizenship status. Within the Federation, while the Malay states were protectorates of the United Kingdom, Penang and Malacca remained British colonial territories. Like the Malayan Union before it, the Federation did not include Singapore, despite its traditional connections with Malaya. The Malaya Agreement was formulated by the British–Malay Pleno Conference between June and December 1946. At the end of the meeting, the Pleno Conference produced a 100-page "Blue Book." It was signed on 21 January 1948 at King House by the Malay rulers, and by Sir Edward Gent as the representative of the British government. The Agreement superseded the Agreement creating the Malayan Union, and prepared for the establishment of the Federation of Malaya on 1 February 1948. The position of the Malay rulers was also restored. The Federation became independent from British colonial rule and became an independent member of the Commonwealth of Nations on 31 August 1957. In 1963, the Federation was reconstituted as "Malaysia" when it federated with the British territories of Singapore, Sarawak, and North Borneo; a claim to the latter territory was maintained by the Philippines.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.